CRISPR Therapeutics AG (CRSP) Total Liabilities (2015 - 2026)

CRISPR Therapeutics AG (CRSP) has 12 years of Total Liabilities data on file, last reported at $911.3 million in Q1 2026.

• For the quarter ending Q1 2026, Total Liabilities rose 170.45% year-over-year to $911.3 million; the trailing twelve-month figure through Mar 2026 stood at $911.3 million (up 170.45% YoY), and the FY2025 full-year result was $343.4 million, up 10.8% from the prior year.
• Total Liabilities improved to $911.3 million in Q1 2026, from $343.4 million in the prior quarter.
• In the past five years, Total Liabilities ranged from a high of $911.3 million in Q1 2026 to a low of $310.0 million in Q4 2024.
• A 5-year average of $385.7 million and a median of $358.9 million in 2024 frame the typical range for Total Liabilities.
• Across the five-year window, Total Liabilities fell 11.86% in 2024 and surged 170.45% in 2026, its largest moves.
• Tracing CRSP's Total Liabilities over 5 years: stood at $367.6 million in 2022, then dropped by 5.66% to $346.8 million in 2023, then declined by 10.62% to $310.0 million in 2024, then advanced by 10.8% to $343.4 million in 2025, then surged by 165.34% to $911.3 million in 2026.
• Business Quant data shows CRSP's Total Liabilities at $911.3 million in Q1 2026, $343.4 million in Q4 2025, and $329.3 million in Q3 2025.